Die Rolle des PSMA-PET/CT bei Patienten mit metastasiertem Prostatakarzinom
Prostate-specific membrane antigen (PSMA) positron emission tomography-computed tomography (PET-CT) imaging for the localization of prostate cancer is increasingly available in Germany. The advances and limitations in different disease stages are reviewed. As the clinical relevance of oligometastati...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Deutsch |
| Veröffentlicht: |
4. Oktober 2017
|
| In: |
Der Urologe
Year: 2017, Jahrgang: 56, Heft: 11, Pages: 1410-1416 |
| DOI: | 10.1007/s00120-017-0513-2 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1007/s00120-017-0513-2 Verlag, Volltext: https://link.springer.com/article/10.1007/s00120-017-0513-2 |
| Verfasserangaben: | J. von Hardenberg, K.-A. Büsing, P. Nuhn, M. Ritter |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 157791208X | ||
| 003 | DE-627 | ||
| 005 | 20230426230739.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180725s2017 xx |||||o 00| ||ger c | ||
| 024 | 7 | |a 10.1007/s00120-017-0513-2 |2 doi | |
| 035 | |a (DE-627)157791208X | ||
| 035 | |a (DE-576)50791208X | ||
| 035 | |a (DE-599)BSZ50791208X | ||
| 035 | |a (OCoLC)1341014402 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a ger | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Hardenberg, Jost von |d 1982- |e VerfasserIn |0 (DE-588)1020494328 |0 (DE-627)688149278 |0 (DE-576)360578241 |4 aut | |
| 245 | 1 | 4 | |a Die Rolle des PSMA-PET/CT bei Patienten mit metastasiertem Prostatakarzinom |c J. von Hardenberg, K.-A. Büsing, P. Nuhn, M. Ritter |
| 264 | 1 | |c 4. Oktober 2017 | |
| 300 | |b Illustrationen | ||
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 25.07.2018 | ||
| 520 | |a Prostate-specific membrane antigen (PSMA) positron emission tomography-computed tomography (PET-CT) imaging for the localization of prostate cancer is increasingly available in Germany. The advances and limitations in different disease stages are reviewed. As the clinical relevance of oligometastatic disease in primary cancer detected by PSMA PET-CT imaging is not yet completely understood, it should only be used in clinical trials. In recurrent prostate cancer after therapy with curative intent, PSMA PET-CT shows encouraging potential for the planning of salvage therapy. In metastatic castration-resistant prostate cancer evidence for its use is not available. | ||
| 650 | 4 | |a Castration-resistant prostate cancer (CRPC) | |
| 650 | 4 | |a Kastrationsresistentes Prostatakarzinom (CRPC) | |
| 650 | 4 | |a Oligometastases | |
| 650 | 4 | |a Oligometastasierung | |
| 650 | 4 | |a Primärdiagnostik | |
| 650 | 4 | |a Primary diagnostic | |
| 650 | 4 | |a Prostatectomy | |
| 650 | 4 | |a Prostatektomie | |
| 650 | 4 | |a radical | |
| 650 | 4 | |a radikale | |
| 650 | 4 | |a Recurrence | |
| 650 | 4 | |a Rezidivdiagnostik | |
| 700 | 1 | |a Büsing, Karen-Anett |d 1970- |e VerfasserIn |0 (DE-588)123814634 |0 (DE-627)706436032 |0 (DE-576)293891222 |4 aut | |
| 700 | 1 | |a Nuhn, Philipp |d 1981- |e VerfasserIn |0 (DE-588)136112951 |0 (DE-627)694090808 |0 (DE-576)30083909X |4 aut | |
| 700 | 1 | |a Ritter, Manuel |d 1979- |e VerfasserIn |0 (DE-588)1030329915 |0 (DE-627)73508436X |0 (DE-576)378128256 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Der Urologe |d [Berlin : Springer Medizin, 2005 |g 56(2017), 11, Seite 1410-1416 |h Online-Ressource |w (DE-627)101704192X |w (DE-600)2925337-8 |w (DE-576)501620842 |7 nnas |a Die Rolle des PSMA-PET/CT bei Patienten mit metastasiertem Prostatakarzinom |
| 773 | 1 | 8 | |g volume:56 |g year:2017 |g number:11 |g pages:1410-1416 |g extent:7 |a Die Rolle des PSMA-PET/CT bei Patienten mit metastasiertem Prostatakarzinom |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00120-017-0513-2 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://link.springer.com/article/10.1007/s00120-017-0513-2 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180725 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 1030329915 |a Ritter, Manuel |m 1030329915:Ritter, Manuel |d 60000 |d 63100 |e 60000PR1030329915 |e 63100PR1030329915 |k 0/60000/ |k 1/60000/63100/ |p 4 |y j | ||
| 998 | |g 136112951 |a Nuhn, Philipp |m 136112951:Nuhn, Philipp |d 60000 |d 63100 |e 60000PN136112951 |e 63100PN136112951 |k 0/60000/ |k 1/60000/63100/ |p 3 | ||
| 998 | |g 123814634 |a Büsing, Karen-Anett |m 123814634:Büsing, Karen-Anett |d 60000 |d 62900 |e 60000PB123814634 |e 62900PB123814634 |k 0/60000/ |k 1/60000/62900/ |p 2 | ||
| 998 | |g 1020494328 |a Hardenberg, Jost von |m 1020494328:Hardenberg, Jost von |d 60000 |d 63100 |e 60000PH1020494328 |e 63100PH1020494328 |k 0/60000/ |k 1/60000/63100/ |p 1 |x j | ||
| 999 | |a KXP-PPN157791208X |e 3019470188 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["J. von Hardenberg, K.-A. Büsing, P. Nuhn, M. Ritter"]},"person":[{"family":"Hardenberg","display":"Hardenberg, Jost von","given":"Jost von","role":"aut"},{"role":"aut","given":"Karen-Anett","display":"Büsing, Karen-Anett","family":"Büsing"},{"given":"Philipp","role":"aut","display":"Nuhn, Philipp","family":"Nuhn"},{"display":"Ritter, Manuel","role":"aut","given":"Manuel","family":"Ritter"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"recId":"157791208X","origin":[{"dateIssuedDisp":"4. Oktober 2017","dateIssuedKey":"2017"}],"physDesc":[{"noteIll":"Illustrationen","extent":"7 S."}],"id":{"eki":["157791208X"],"doi":["10.1007/s00120-017-0513-2"]},"relHost":[{"name":{"displayForm":["Deutsche Gesellschaft für Urologie"]},"physDesc":[{"extent":"Online-Ressource"}],"disp":"Die Rolle des PSMA-PET/CT bei Patienten mit metastasiertem ProstatakarzinomDer Urologe","id":{"eki":["101704192X"],"zdb":["2925337-8"]},"corporate":[{"display":"Deutsche Gesellschaft für Urologie","role":"isb"}],"note":["Gesehen am 05.07.2022"],"type":{"bibl":"periodical","media":"Online-Ressource"},"origin":[{"dateIssuedDisp":"[2005-2022]","publisher":"Springer Medizin","publisherPlace":"[Berlin ; Heidelberg ; New York]"}],"recId":"101704192X","title":[{"title":"Der Urologe","title_sort":"Urologe"}],"part":{"text":"56(2017), 11, Seite 1410-1416","year":"2017","volume":"56","issue":"11","pages":"1410-1416","extent":"7"},"language":["ger"],"pubHistory":["Volume 44, issue 7 (July 2005)-volume 61, issue 5 (May 2022)"]}],"note":["Gesehen am 25.07.2018"],"title":[{"title":"Die Rolle des PSMA-PET/CT bei Patienten mit metastasiertem Prostatakarzinom","title_sort":"Rolle des PSMA-PET/CT bei Patienten mit metastasiertem Prostatakarzinom"}],"language":["ger"]} | ||
| SRT | |a HARDENBERGROLLEDESPS4201 | ||